AUTHOR=Permsuwan Unchalee , Deerochanawong Chaicharn 

TITLE=Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand

JOURNAL=Frontiers in Public Health

VOLUME=Volume 12 - 2024

YEAR=2025

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1415908

DOI=10.3389/fpubh.2024.1415908

ISSN=2296-2565

ABSTRACT=ObjectiveThis study aimed to assess the financial impact of different adoption rates of insulin glargine (IGlar) treatment compared to isophane protamine (neutral protamine hagedorn [NPH]) insulin treatment for patients with type-2 diabetes (T2D) and severe hypoglycemia in Thailand from the payer’s perspective.MethodsThe budget impact analysis (BIA) model over a period of 5 years was used to estimate the net budget impact (NBI) of IGlar treatment by comparing the total budget expenditures under two scenarios: scenario 1 involved only NPH insulin and scenario 2 included the introduction of IGlar. The total budget included either the cost of insulin or a combination of the costs of insulin and the expense related to severe hypoglycemia. Scenario 2 started at 20% uptake of IGlar and a yearly increase of 20%. NBI was calculated as the difference between the total budgets of scenarios 1 and 2. NBI and one-way sensitivity analyses were conducted for evaluation.ResultsConsidering only the cost of insulin, the use of IGlar for patients with T2D and severe hypoglycemia resulted in a yearly average NBI of 174.9 million Thai baht (THB) (5.1 million USD). However, when the cost related to severe hypoglycemia was included, the total budget incurred from scenario 2 was less than that of scenario 1, leading to a negative NBI or cost savings.ConclusionThe NBI of IGlar adoption would be substantial when considering only the cost of insulin; however, the significant benefit of IGlar in terms of a lower rate of severe hypoglycemia compared with NPH insulin would clearly offset the additional cost of IGlar.